NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I’m not sure if it was also noted here earlier on this board that another error with this paper was the IDH mutation issue… I’m assuming that their 3rd “reason for failure” was that IDH was not noted. But many of us will remember that we waited many, many months during Covid for the company to actually obtain that data by testing the tumor tissues, and that the IDH data was given in the JAMA article. It was even noted in the TM article (the interim paper) that the company intended to obtain this data. And yet these four doctors claimed it was not given, even though the patient IDH data was provided in JAMA. From their hit piece article:

3—Reason for failure: Absence of biomarker data inhibits our understanding of the reasons behind the “tail” of long-term survivors in the trial.
Lesson learned: Need to include biomarker data via longitudinal sampling during the trial.

I knew we couldn’t trust Reardon.